Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 470-474

  Culine, S ^a,c   Kattan, J ^a   Zanetta, S ^b   Theodore C ^a   Fizazi, K ^a   Droz, J P ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE LÉON BÉRARD   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

Chemotherapy; Doxorubicin; Estramustine phosphate; Hormone resistant prostate cancer

Indexed keywords

DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HISTOPATHOLOGY; HORMONE RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEUTROPENIA; PROSTATE CANCER; QUALITY OF LIFE; SURVIVAL TIME;

ADULT; AGED; ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0031724010     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00010     Document Type: Article

References (20)

1. Dawson NA. Treatment of progressive metastatic prostate cancer. Oncology 1993;7:17-27.
2. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15:382-8.
3. Mani S, Vogelzang NJ. Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? Hematol Oncol Clin North Am 1996;10:749-68.
4. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
5. Miller AB, Hoogstraten B, Staquet B, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
6. Eisenberger MA, Abrams JS. Chemotherapy for prostatic carcinoma. Semin Urol 1988;6:303-10.
7. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-109.
8. Torti FM, Aston D, Lum BL, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1983;1:477-82.
9. Francini G, Petrioli R, Manganelli A, et al. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 1993;67:1430-6.
10. Rangel C, Matzkin H, Soloway MS. Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. Urology 1992;39:577-82.
11. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 1994;12:683-8.
12. Stearns ME, Wang M, Tew KD, et al. Estramustine binds a MAP-1 like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU-145 cells. J Cell Biol 1988;107:2647-56.
13. Dahllof B, Billstrom A, Cabral F, et al. Estramustine depolymerases microtubules by binding to tubulin. Cancer Res 1993;53:4573-81.
14. Speicher LA, Barone LR, Chapman AE, et al. P-glycoprotein binding and modulation of the MDR phenotype by estramustine. J Natl Cancer Inst 1994;86:688-94.
15. Yang CPH, Shen HJ, Horwitz SB. Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst 1994;86:723-5.
16. Hernes EH, Fossa SD, Vaage S, Ogreid P, Heilo A, Paus E. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. Br J Cancer 1997;76:93-9.
17. Smith CD, Zilfou JT, Zhang X, Hudes GR, Tew KD. Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins. Cancer 1995;75:2591-604.
18. Kelly WK, Slovin S, Scher HI. Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer. Semin Oncol 1996;23(suppl 14):8-14.
19. DeSpain JD. Dermatologie toxicity of chemotherapy. Semin Oncol 1992;19:501-7.
20. Tannock IF, Osoba D, Stockier MR. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.